A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Official Title

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] With MK-3475 [Pembrolizumab] Coformulation) in Participants With Relapsed or Refractory Hematological Malignancies


The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following administration of pembrolizumab/vibostolimab. In addition, this study will characterize pharmacokinetic (PK) profile of vibostolimab (MK-7684).

Trial Description

Primary Outcome:

  • Number of Participants with a Dose-Limiting Toxicity (DLT)
  • Number of Participants Who Experienced an Adverse Event (AE)
  • Number of Participants Who Discontinued Study Treatment Due to an AE
Secondary Outcome:
  • Objective Response Rate (ORR)
  • Duration of Response (DOR)
  • Disease Control Rate (DCR)
  • Lowest Plasma Concentration (Ctrough) of Vibostolimab
  • Maximum Concentration (Cmax) of Vibostolimab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society